

# Antonino Musolino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6214027/antonino-musolino-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

3,346  
citations

21  
h-index

57  
g-index

135  
ext. papers

4,339  
ext. citations

5.1  
avg, IF

4.67  
L-index

#	Paper	IF	Citations
85	Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1789-96	2.2	784
84	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1836-1846	59.2	610
83	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 27-39 <sup>1-7</sup>	39 <sup>1-7</sup>	413
82	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1989-95	2.2	284
81	Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. <i>Cancer</i> , <b>2011</b> , 117, 1837-46	6.4	99
80	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. <i>Breast</i> , <b>2007</b> , 16, 280-92	3.6	97
79	1587P SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a Northern Italy virus epicenter area. <i>Annals of Oncology</i> , <b>2021</b> , 32, S1142	10.3	78
78	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2328-2333	10.3	77
77	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 18	8.3	67
76	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 573-584	13.4	65
75	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , <b>2015</b> , 20, 1001-10	5.7	59
74	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1000-1000	2.2	56
73	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 418-423	10.3	40
72	Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , <b>2011</b> , 117, 964-73	6.4	35
71	Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2006</b> , 29, 171-7	2.7	34
70	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 237-246	7.5	30
69	Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	29

68	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , <b>2020</b> , 13, 410-422	4.9	25
67	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , <b>2019</b> , 48, 7-16	3.6	24
66	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 501-501	2.2	23
65	Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2362-8	2.2	22
64	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1455-1464	21.7	20
63	Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis <b>2020</b> ,		19
62	A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 91, 203-5	4.4	18
61	Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 507-507	2.2	18
60	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 14-9	3.5	17
59	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. <i>Breast</i> , <b>2017</b> , 35, 115-121	3.6	16
58	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 601-609	4.4	16
57	Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 84-6	4.5	16
56	p73 and p53 pathway in human breast cancers. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1451-3; author reply 1453-4	2.2	15
55	The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1051-7	3.5	14
54	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 472-7	3.5	13
53	Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 759	5.3	12
52	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2017</b> , 17, e65-e75	3	12
51	Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase. <i>Tumori</i> , <b>2004</b> , 90, 276-279	1.7	11

50	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. <i>Tumori</i> , <b>2005</b> , 91, 505-512	1.7	11
49	Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 43, 1-7	14.4	9
48	Accuracy and Relative Value of Bone Marrow Aspiration in the Detection of Lymphoid Infiltration in non-Hodgkin Lymphoma. <i>Tumori</i> , <b>2010</b> , 96, 24-27	1.7	9
47	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1405-1406	10.3	8
46	Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. <i>Cancer</i> , <b>2005</b> , 103, 2109-17	6.4	8
45	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 149, 102927	7	7
44	Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5843-5851	12.9	7
43	Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. <i>Haematologica</i> , <b>2007</b> , 92, e59-61	6.6	6
42	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer <b>2015</b> ,		6
41	Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review. <i>Acta Biomedica</i> , <b>2017</b> , 88, 329-333	3.2	6
40	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	6
39	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. <i>Annals of Oncology</i> , <b>2020</b> , 31, S304-S305	10.3	6
38	Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study. <i>Acta Biomedica</i> , <b>2016</b> , 87, 54-63	3.2	6
37	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 544-544	2.2	5
36	Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 13090-13090	2.2	4
35	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 409-424	4.5	4
34	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 133-141	7.5	4
33	Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. <i>Cancer Medicine</i> , <b>2021</b> , 10, 6855-6867	4.8	4

32	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , <b>2022</b> , 82, 1646-1657	10.1	4
31	Niraparib for Advanced Breast Cancer with Germline and Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5482-5491	12.9	3
30	Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 990-993	3.6	2
29	Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 192	5.3	2
28	PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. <i>Annals of Oncology</i> , <b>2019</b> , 30, v760	10.3	2
27	Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?. <i>Lung Cancer</i> , <b>2005</b> , 50, 419-20	5.9	2
26	Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study <b>2013</b>		2
25	Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 582-582	2.2	2
24	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged $\geq 65$ years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , <b>2018</b> , 9, 31877-31887	3.3	2
23	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). <i>ESMO Open</i> , <b>2021</b> , 6, 100019	6	2
22	Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 700853	5.3	2
21	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , <b>2021</b> , 48, 208-225	5.5	2
20	Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS651-TPS651	2.2	1
19	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , <b>2019</b> , 17, 207	11.4	1
18	Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. <i>European Journal of Cancer</i> , <b>2018</b> , 88, 10-20	7.5	1
17	Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe. <i>Breast</i> , <b>2021</b> , 59, 232-238	3.6	1
16	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , <b>2022</b> , 82, PD8-01-PD8-01	10.1	1
15	Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1

14	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.. <i>ESMO Open</i> , <b>2022</b> , 7, 100483	6	1
13	Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?. <i>Breast Care</i> , <b>2022</b> , 17, 10-15	2.4	0
12	Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211043427	1.8	0
11	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 190, 415-424	4.4	0
10	Breast Cancer in Italy: Stage and Region Distribution.. <i>Breast Cancer: Targets and Therapy</i> , <b>2022</b> , 14, 125-131	1.3	0
9	FCGR, Cetuximab, and Colorectal Cancer Survival-Letter. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4958	12.9	
8	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e304	21.7	
7	Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , <b>2011</b> , 117, 3531-3531	6.4	
6	Family history for BRCA1 and BRCA2 mutations in patients with pancreatic cancer: An observational, population-based study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15236-e15236	2.2	
5	Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 594-594	2.2	
4	Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1076-1076	2.2	
3	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1095-1095	2.2	
2	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , <b>2020</b> , 15, 30-37	2.4	
1	Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors. <i>JAMA Oncology</i> , <b>2018</b> , 4, 132	13.4	